The calls listed on this page are closed for the submission of full proposals (for single-stage calls) or short proposals (for two-stage calls). The status of each call is summarised below; for more information, please visit the individual call pages.
IHI call 1
IHI call 1 is a single-stage call that was launched on 28 June 2022 with topics on cancer, neurodegenerative diseases, and health data.
Call status: The five projects resulting from the call were launched in spring 2023
IHI call 2
IHI call 2 is a two-stage call that was launched 28 June 2022 with topics on cardiovascular disease and early feasibility studies.
Call status: The deadline for short proposals was 20 September 2022 and the evaluations were held in autumn 2022. The top-ranked consortium for each topic was invited to link up with the industry consortium described in the topic text and submit a full proposal by 28 February 2023. The full proposals have been evaluated and the successful consortia have been invited to start grant agreement preparation.
IHI call 3
IHI call 3 is a single-stage call that was launched on 13 December 2022 with topics on a screening platform for diseases of unmet public health need; patient-generated evidence; hospital efficiencies; advanced therapies for rare diseases; and digital technologies for mental disorders.
Call status: The deadline for full proposals was 15 March 2023 and the evaluations were held in spring 2023. We have informed applicants of the results of the evaluation and invited successful consortia to start grant agreement preparation.
IHI - call 4
IHI call 4 is a two-stage call that was launched on 27 July 2023 with topics on the 3Rs, patient-centric blood sample collection, clinical trials, and the environmental impacts of healthcare.
Call status: The deadline for short proposals was 8 November 2023. Eligible proposals will be evaluated by independent experts and the top-ranked consortia will be invited to link up with the industry consortium described in the top text and submit a full proposal by 23 April 2024.